

Available online at [www.sciencedirect.com](http://www.sciencedirect.com)

SciVerse ScienceDirect

journal homepage: [www.elsevier.com/locate/jopr](http://www.elsevier.com/locate/jopr)

## Original Article

# Evaluation of *in vitro* anthelmintic activities of novel 1,2,3 – benzotriazole derivatives synthesized in ultrasonic and solvent free conditions

M.S. Sudhir<sup>a,c</sup>, R. Venkata Nadh<sup>b,\*</sup><sup>a</sup> Department of Chemistry, Sri Subbaraya and Narayana College, Narasaraopet 522 601, Andhra Pradesh, India<sup>b</sup> School of Biotechnology, Vignan University, Vadlamudi, Guntur 522213, India

## ARTICLE INFO

## Article history:

Received 14 November 2012

Accepted 9 January 2013

Available online 4 February 2013

## Keywords:

Anthelmintic activities

1,2,3 – benzotriazoles

*Pheretima posthuma*

Solvent-free condition

Ultrasonication

## ABSTRACT

**Objectives:** To determine anthelmintic activity of the synthesized novel 1,2,3 – benzotriazole derivatives under ultrasonication in solvent free conditions.

**Methods:** Newer “1–(1H–benzo[d][1,2,3]triazole-1-carbonyl) derivatives” (5A–5P) were synthesized by using “1H–benzo[d][1,2,3]triazole” (1) as the starting material under ultrasonicated and solvent-free conditions. The resulting products were isolated and characterized by melting points and spectral studies. All the products were assayed for anthelmintic activity against *Pheretima posthuma* using albendazole and mebendazole as reference compounds.

**Results:** All the newer 1,2,3 – benzotriazole derivatives synthesized by ultrasound activation in solvent–free condition were obtained in moderate to good yields in the range of 71–82%. The data interpretation of the spectral values with reference to standard values confirmed the structures of the synthesized compounds. Out of the sixteen synthesized derivatives, four compounds (5B, 5F, 5J and 5N) showed anthelmintic activity in dose-dependent manner giving shortest time of paralysis and death with different concentrations of the derivatives. Among these four derivatives, 5J showed superior activity.

**Conclusion:** Out of the sixteen synthesized derivatives, four compounds (5B, 5F, 5J and 5N) containing *p*-nitrophenyl substituent attached to azo group of benzotriazole moieties exhibited equal or comparable anthelmintic activity with reference to albendazole. The superior activity of compound 5J might be due to attachment of additional *p*-nitrophenyl substituent to the cyano group.

Copyright © 2013, JPR Solutions; Published by Reed Elsevier India Pvt. Ltd. All rights reserved.

## 1. Introduction

The heterocyclic system containing benzotriazole moieties system is of wide interest because of their diverse biological

activities<sup>1,2</sup> including anticonvulsant and anti-inflammatory activities,<sup>3</sup> diuretic,<sup>4</sup> analgesic,<sup>5</sup> pesticidal.<sup>6</sup> Recent publications reported synthetic protocols in solvent-less conditions<sup>7–9</sup> and in presence of ultrasonic radiation.<sup>10–13</sup> Anthelmintic

\* Corresponding author. Tel.: +91 9441027105.

E-mail addresses: [sudheer45147@yahoo.com](mailto:sudheer45147@yahoo.com) (M.S. Sudhir), [doctornadh@yahoo.co.in](mailto:doctornadh@yahoo.co.in) (R. Venkata Nadh).

<sup>c</sup> Tel.: +91 9490645147.

infections are now being recognized as cause of much chronic ill health amongst the tropical people. More than half of population in the world suffers from worm infection of one or the other.<sup>14</sup> Hence, newer 1,2,3 – benzotriazole derivatives were synthesized in ultrasonic and solvent-free conditions and their anthelmintic activities were studied.

## 2. Materials and methods

All organic solvents and chemicals were of analytical grade. Albendazole (Bandy Mankind Pharma Ltd., New Delhi) and Mebendazole (Mansukhlal Tribhovandas & Company, Mumbai) were used for anthelmintic activities.

For synthesis of benzotriazole derivatives, a 12 mm wide and 140 mm long probe (of an UP 400S ultrasonic processor) was immersed directly into the reaction mixture at room temperature. The operating frequency and the output power were 24 kHz and 240 W respectively. The synthesized compounds were characterized by spectral studies using Perkin Elmer 1600 series Fourier transformer-infrared spectrophotometer in KBr-pellet method; <sup>1</sup>H NMR, Bruker 400 MHz NMR spectrometer (Bruker Bioscience, Billerica, MA, USA) in MeOD using TMS as internal standard.

### 2.1. Scheme for the synthesis of the compounds

After suitable modifications to the classical synthesis carried out by other workers,<sup>15-17</sup> sixteen new benzotriazole derivatives were synthesized under green conditions (viz., ultrasonication and solvent free conditions) by the addition of diazotization step (Fig. 1).

### 2.2. Methodology for in vitro anthelmintic activity

In vitro anthelmintic activity for the synthesized compounds was studied with minor modifications to the standard


method.<sup>18</sup> *Pheretima posthuma* (earthworm) obtained from Agricultural Department, Guntur, India, of nearly equal size (length:  $9 \pm 1.5$  cm and width: 0.1–0.2 cm). Solutions of the all compounds and control drugs (albendazole and mebendazole) were prepared freshly. The drugs and synthesized compounds were dissolved in minimum quantity of DMF and adjusted to 15 ml volume with Tween-80 (3%) in normal saline. The test concentrations (1, 2.5 and 5% w/v) were taken in petri dishes (4 inches).

A group of six earthworms were released in to each of 15 ml of control drugs and the test suspensions (1, 2.5 and 5% w/v each). Observations were made for the time taken to paralysis and death of individual worms up to 4 h of the test period. Each petri dish was placed with 6 worms and observed for paralysis (or) death. The mean time for paralysis was noted when no movement of any sort could be observed, except when the worm was shaken vigorously. The death time of worm (min) was recorded after ascertaining that worms neither moved when shaken nor when given external stimuli. Death was concluded when the worms lost their motility followed with fading away of their body colors.

## 3. Results

All the newer 1,2,3-benzotriazole derivatives synthesized by ultrasound activation in solvent-free condition were obtained in moderate to good yields in the range of 71–82%. The synthesized derivatives were characterized by FTIR and <sup>1</sup>H NMR values measured in  $\text{cm}^{-1}$  and  $\delta$  (ppm) respectively. The data was interpreted with reference to standard values<sup>19,20</sup> and given in Table 1 for some of the synthesized compounds.

All synthesized compounds were tested for anthelmintic activity and compared with the standard anthelmintic substances i.e., mebendazole and albendazole under the same conditions. The time taken for complete paralysis and death are reported in Table 2.



5A – D: Ar = C<sub>6</sub>H<sub>5</sub>; 5E – H: Ar = C<sub>4</sub>H<sub>3</sub>O; 5I – L: Ar = C<sub>6</sub>H<sub>4</sub>NO<sub>2</sub> and 5M – P: Ar = C<sub>6</sub>H<sub>4</sub>Cl

5A, E, I, M: X = C<sub>6</sub>H<sub>5</sub>; 5B, F, J, N: X = C<sub>6</sub>H<sub>4</sub>NO<sub>2</sub>; 5C, G, K, O: X = C<sub>6</sub>H<sub>4</sub>Cl and 5D, H, L, P: X = C<sub>6</sub>H<sub>4</sub>Br

Note: US = Ultrasonication

Fig. 1 – Scheme of synthesis.

**Table 1 – Spectral characterization of some of the synthesized compounds.**

Compound code	Compound name	IR bands (in $\text{cm}^{-1}$ )	$^1\text{H}$ NMR peaks $\delta$ (in ppm)
5A	1-(1H-benzo[d][1, 2, 3] triazole-1-carbonyl)-3, 5-diphenylformazan	1696.66 (Ar C=C, stretch); 1603.37 (N=N, stretch), 1542.28 (N-H, stretch), 1256.37 (Aryl C-N, stretch), 1007.57 (Aniline C-N, stretch) and 737.28 (CHO – deformation).	7.0 (1H, s, N-H), 7.06 (1H, d, C-H), 7.33 (2H, d, C-H), 7.40 (2H, d, C-H), 7.45–7.48 (2H, m, C-H), 7.56–7.59 (3H, m, C-H), 7.83 (2H, d, C-H) and 7.96 (2H, d, C-H).
5B	1-(1H-benzo [d][1, 2, 3] triazole-1-carbonyl)-5-(4-nitrophenyl)-3-phenyl formazan	1698.47 (Ar C=C, stretch); 1593.99 (N=N, stretch), 1495.50 (Ar-NO <sub>2</sub> , stretch), 1301.09 (Aryl C-N, stretch), 1206.78 (Aniline C-N, stretch), 843.07 (p – disubstitution, deformation) and 739.50 (CHO – deformation).	7.0 (1H, s, N-H), 7.18 (2H, d, C-H), 7.40 (2H, d, C-H), 7.52–7.59 (3H, m, C-H), 7.83 (2H, d, C-H), 7.96 (2H, d, C-H) and 8.10 (2H, d, C-H).
5G	1-(1H-benzo[d][1, 2, 3]triazole-1-carbonyl)-5-(4-chlorophenyl)-3-(furan-2-yl) formazan	3649.31 (Amide-CONH, stretch), 1594.63 (N=N, stretch), 1485.68 (Furan Ring, C=C, stretch), 1206.43 (Aniline C-N, stretch), 1007.96 (C-O-C, stretch), 820.27 (p – disubstitution, stretch), 740.62 (CHO deformation) and 539.68 (C – Cl, deformation)	6.52 (1H, m, Furan C-H), 6.54 (1H, d, Furan C-H), 7.0 (1H, s, N-H), 7.27 (2H, d, C-H), 7.40 (2H, d, C-H), 7.49 (2H, d, C-H), 7.75 (1H, d, Furan C-H) and 7.96 (2H, d, C-H)
5H	1-(1H-benzo[d][1, 2, 3] triazole-1-carbonyl)-5-(4-bromophenyl)-3-(furan-2-yl) formazan	3652.10 (Amide-CONH, stretch), 1722.17 (Furan Ring, stretch), 1622.31 (N=N, stretch), 1511.18 (Ar C=C, stretch), 1457.07 (Furan Ring C=C, stretch), 1202.93 (Aniline C-N, stretch), 1005.36 (C-O-C, stretch), 875.16 (p – disubstitution, deformation), 773.52 (CHO deformation) and 515.35 (C-Br, deformation).	6.52 (1H, m, Furan C-H), 6.54 (1H, d, Furan C-H), 7.0 (1H, s, N-H), 7.22 (2H, d, C-H), 7.40 (2H, d, C-H), 7.75 (1H, d, Furan C-H), 7.76 (2H, d, C-H) and 7.96 (2H, d, C-H).
5M	1-(1H-benzo[d][1, 2, 3] triazole-1-carbonyl)-3-(4-chlorophenyl)-5-phenyl formazan	3650.62 (Amide-CONH), 1706.94 (Ar, C=C, stretch), 1593.76 (N=N, stretch), 1513.71 (N-H, stretch), 1264.35 (Aryl C-N, stretch), 1204.85 (Aniline C-N, stretch), 820.56 (p – disubstitution, stretch), 772.75 (CHO – deformation) and 605.30 (C-Cl, deformation).	7.0 (1H, s, N-H), 7.06 (1H, d, C-H), 7.33 (2H, d, C-H), 7.40 (2H, d, C-H), 7.45 (2H, d, C-H), 7.52 (2H, d, C-H), 7.77 (2H, d, C-H) and 7.96 (2H, d, C-H).
5O	1-(1H-benzo[d][1, 2, 3] triazole-1-carbonyl)-3,5-bis(4-chloro-phenyl) formazan	1710.45 (Ar, C=C, stretch), 1593.50 (N=N, stretch), 1486.45 (N-H, stretch), 1256.86 (Aryl C-N, stretch), 1143.95 (Aniline C-N, stretch), 827.70 (p – disubstitution, deformation), 773.01 (CHO – deformation) and 620.81 (C-Cl, deformation)	7.0 (1H, s, N-H), 7.27 (2H, d, C-H), 7.40 (2H, d, C-H), 7.49 (2H, d, C-H), 7.52 (2H, d, C-H), 7.77 (2H, d, C-H) and 7.96 (2H, d, C-H).

**Table 2 – Anthelmintic activity of 1,2,3 – benzotriazole derivatives.**

S. no.	Compound code	Concentration (% w/v)	Time taken in minutes ( $\pm$ SD)	
			Paralysis (P)	Death (D)
1	5A	1	26.12 $\pm$ 0.52	75.12 $\pm$ 0.46
		2.5	20.32 $\pm$ 0.29	68.23 $\pm$ 0.33
		5	15.23 $\pm$ 0.30	61.22 $\pm$ 0.38
2	5B	1	16.22 $\pm$ 0.14	38.55 $\pm$ 0.23
		2.5	14.23 $\pm$ 0.14	30.21 $\pm$ 0.29
		5	11.28 $\pm$ 0.20	24.29 $\pm$ 0.21
3	5C	1	19.44 $\pm$ 0.35	69.23 $\pm$ 0.43
		2.5	18.18 $\pm$ 0.23	61.17 $\pm$ 0.12
		5	17.35 $\pm$ 0.41	52.34 $\pm$ 0.19
4	5D	1	18.12 $\pm$ 0.33	67.33 $\pm$ 0.51
		2.5	17.48 $\pm$ 0.41	59.27 $\pm$ 0.18
		5	16.45 $\pm$ 0.40	52.40 $\pm$ 0.12
5	5E	1	26.36 $\pm$ 0.36	66.22 $\pm$ 0.32
		2.5	21.45 $\pm$ 0.29	56.22 $\pm$ 0.28
		5	17.56 $\pm$ 0.33	48.23 $\pm$ 0.39
6	5F	1	15.45 $\pm$ 0.41	39.12 $\pm$ 0.18
		2.5	14.11 $\pm$ 0.29	31.21 $\pm$ 0.20
		5	11.44 $\pm$ 0.12	24.39 $\pm$ 0.19
7	5G	1	18.38 $\pm$ 0.33	75.43 $\pm$ 0.58
		2.5	17.41 $\pm$ 0.23	63.28 $\pm$ 0.26
		5	16.32 $\pm$ 0.13	53.38 $\pm$ 0.21
8	5H	1	18.11 $\pm$ 0.21	70.13 $\pm$ 0.23
		2.5	17.31 $\pm$ 0.11	62.48 $\pm$ 0.16
		5	16.12 $\pm$ 0.17	55.38 $\pm$ 0.11
9	5I	1	25.52 $\pm$ 1.36	45.45 $\pm$ 1.20
		2.5	20.35 $\pm$ 0.37	39.33 $\pm$ 0.33
		5	15.23 $\pm$ 0.40	33.41 $\pm$ 0.29
10	5J	1	15.25 $\pm$ 0.14	36.12 $\pm$ 0.12
		2.5	13.11 $\pm$ 0.19	30.21 $\pm$ 0.26
		5	10.44 $\pm$ 0.12	23.39 $\pm$ 0.11
11	5K	1	18.21 $\pm$ 0.29	69.21 $\pm$ 0.63
		2.5	16.11 $\pm$ 0.23	58.46 $\pm$ 0.19
		5	14.39 $\pm$ 0.27	51.23 $\pm$ 0.28
12	5L	1	19.40 $\pm$ 0.31	68.23 $\pm$ 0.31
		2.5	18.22 $\pm$ 0.12	62.17 $\pm$ 0.18
		5	17.39 $\pm$ 0.18	56.34 $\pm$ 0.23
13	5M	1	27.22 $\pm$ 0.42	66.23 $\pm$ 0.33
		2.5	21.35 $\pm$ 0.28	59.46 $\pm$ 0.39
		5	19.45 $\pm$ 0.33	49.38 $\pm$ 0.37
14	5N	1	16.52 $\pm$ 0.17	36.55 $\pm$ 0.20
		2.5	14.38 $\pm$ 0.18	29.21 $\pm$ 0.26
		5	11.29 $\pm$ 0.28	20.29 $\pm$ 0.11
15	5O	1	19.18 $\pm$ 0.36	66.21 $\pm$ 0.32
		2.5	17.12 $\pm$ 0.23	58.38 $\pm$ 0.27
		5	15.32 $\pm$ 0.19	49.28 $\pm$ 0.13
16	5P	1	18.21 $\pm$ 0.17	68.11 $\pm$ 0.21
		2.5	17.29 $\pm$ 0.13	59.28 $\pm$ 0.14
		5	15.28 $\pm$ 0.21	50.39 $\pm$ 0.32
17	Albendazole	1	15.21 $\pm$ 0.14	34.55 $\pm$ 0.23
		2.5	13.08 $\pm$ 0.24	28.21 $\pm$ 0.18
		5	10.23 $\pm$ 0.19	20.29 $\pm$ 0.21
18	Mebendazole	1	9.11 $\pm$ 0.18	28.17 $\pm$ 0.11
		2.5	7.56 $\pm$ 0.14	21.56 $\pm$ 0.28
		5	5.23 $\pm$ 0.39	17.32 $\pm$ 0.19

Note: results are expressed as mean  $\pm$  SD of six determinations; control worms were alive up to 4 h of observation.

#### 4. Discussion

Newer 1,2,3 – benzotriazole derivatives were synthesized by following green procedure under ultrasonic and solvent free

conditions and characterized by spectral studies. All the synthesized compounds were tested for anthelmintic activity against adult earthworms (*P. posthuma*) due to their anatomical and physiological resemblance with the intestinal roundworm parasites of human beings.<sup>21,22</sup> Albendazole, one of the

reference compound in the present study is effective in a broad range of helminth infections, including round worms, hookworms, whipworms, pinworms and its mechanism of action involves inhibition of the glucose uptake system leading to a lethal depletion of energy reserves in the helminthes.<sup>23</sup> Another reference compound, mebendazole binds to the worm's microtubular-protein 'β-tubulin' and inhibits its polymerization by blocking glucose uptake in the parasite<sup>24-27</sup> and also exhibits potent antitumor property both *in vitro* and *in vivo*.<sup>28</sup>

From the observations made in the present study, higher concentration of the synthesized derivatives exhibited paralytic effect much earlier and the time to death was shorter for worms. Out of the sixteen synthesized derivatives, four compounds (5B, 5F, 5J and 5N) showed anthelmintic activity in dose-dependent manner giving shortest time of paralysis (P) and death (D) with all three concentrations of the derivatives. These four compounds contain *p*-nitrophenyl substituent attached to azo group of benzotriazole moieties and hence, displayed equal or comparable anthelmintic activity with reference to albendazole. Even earlier, best anthelmintic activity was reported for *p*-nitrophenyl substituted benzotriazoles like N<sup>1</sup>-(*p*-nitrophenyl) aminomethylene benzotriazole by Pawar.<sup>29</sup> Among these four derivatives (5B, 5F, 5J and 5N), 5J showed superior activity which might be due to attachment of additional *p*-nitrophenyl substituent to the cyano group.

Though, mebendazole was found to be effective compared to albendazole against the selected worms for the present study (Table 2), for mass treatment of multiple infections with *Ascaris*, hookworm, and *Trichuris*, albendazole was the preferred benzimidazole derivative from the comparative efficacy study of albendazole and mebendazole carried out in Pattani Province–Thailand by Jongsuksuntigul.<sup>30</sup> As the four synthesized compounds showed comparable anthelmintic activity to albendazole, these compounds may also be tested for multiple infections.

Better anthelmintic activity of the four compounds (5B, 5F, 5J and 5N) can be attributed to the *p*-nitrophenyl substituent attached to azo group of benzotriazole moieties. Superior activity of 5J might be due to attachment of additional *p*-nitrophenyl substituent to the cyano group. As the four synthesized compounds showed comparable anthelmintic activity to albendazole, these compounds may also be tested for multiple infections. Finally in conclusion, out of the sixteen 1,2,3 – benzotriazole derivatives, compounds with nitro substituents have shown best anthelmintic activities against *P. posthuma*.

### Conflicts of interest

All authors have none to declare.

### Acknowledgments

The authors are grateful to Chalapathi Institute of Pharmaceutical Sciences, Chalapathi Nagar, Lam, Guntur Dist, Andhra Pradesh, India for providing the necessary research facilities.

### REFERENCES

1. Tasaka A, Tamura N, Matsushita Y, et al. Optically active antifungal azoles. IV. Synthesis and antifungal activity of (2R, 3R)-3-azoyl-2-(substituted phenyl)-1-(1H-1, 2, 4-triazol-1-yl)-2-butanols. *Chem Pharm Bull.* 1995;43(3):432–440.
2. Sanna P, Carta A, Nikookar MER. Synthesis and antitubercular activity of 3-aryl substituted 2-(1H, 2H) benzotriazol-1 (2-yl) acrylonitriles. *Eur J Med Chem.* 2000;35(5):535–543.
3. Dawood KM, Abdel-Gawad H, Rageb EM, Ellithey M, Mohamed HA. Synthesis, anticonvulsant, and anti-inflammatory evaluation of some new benzotriazole and benzofuran-based heterocycles. *Bioorg Med Chem.* 2006;14:3672–3680.
4. Patel JS, Garg CS, Sen DJ. Synthesis of novel N-substituted 2-(1h-benzotriazol-1-yl)-acetohydrazide derivatives as antimicrobial agents. *Int J Drug Dev Res.* 2012;4(2):322–329.
5. Rajasekaran A, Rajagopal KA. Synthesis of some novel triazole derivatives as anti-nociceptive and anti-inflammatory agents. *Acta Pharm.* 2009;59(3):355–364.
6. Mohammad A, Kumar H, Javed SA. Synthesis and pharmacological evaluation of condensed heterocyclic 6-substituted-1, 2, 4-triazolo [3, 4-b]-1,3,4-thiadiazole derivatives of naproxen. *Bioorg Med Chem Lett.* 2007;17(16):4504–4508.
7. Nadeem S, Munawar A, Ahmad S, et al. Solvent-free synthesis of benzthiazole-based quaternary ammonium salts: precursors to ionic liquids. *ARKIVOC.* 2010;7:19–37.
8. Kothakar SA, Rahul RN, Shinde BD. Chlorosulfonic acid catalysed highly efficient solvent-free synthesis of 3,4-dihydropyrimidin-2 (1 H)-ones and thiones. *Ukrainica Bioorganica Acta.* 2006;2:17–21.
9. Rahul RN, Shinde BD. BF<sub>3</sub>.OEt<sub>2</sub> promoted solvent-free synthesis of benzimidazole derivatives. *Chin Chem Lett.* 2006;17(4):453–456.
10. Byung HH, Philip BJ. Organic sonochemistry, ultrasonic acceleration of the reduction of simple and deactivated aryl halides using lithium aluminium hydride. *Tetrahedron Lett.* 1982;23(16):1643–1646.
11. David KS, Klotz H, Parker CR. The effect of ultrasound on the alkaline hydrolysis of nitrophenyl esters. *Tetrahedron Lett.* 1981;22(10):907–908.
12. Duss F, Hansen PE. Ultrasound assisted synthesis of 5, 9-dimethylpentadecane and 5, 9-dimethylhexadecane – the sex pheromones of *Leucoptera coffeella*. *Molecules.* 2007;12:2080–2088.
13. Naglaa MAE, Tamer SS, Mohamed FM. Ultrasound assisted synthesis of some new 1, 3, 4-thiadiazole and bi (1, 3, 4-thiadiazole) derivatives incorporating pyrazolone moiety. *Ultrason Sonochem.* 2009;16:70–74.
14. Nakhare S, Garg SC. Anthelmintic activity of the essential oil of *artemisia pallens* wall. *Anc Sci Life.* 1991;10(3):185–186.
15. Asati KC, Srivastava SK, Srivastava SD. Synthesis of 5-arylidene-2-aryl-3-(benzotriazol acetamidyl)-1, 3-thiazolidine-4-ones as analgesic and anti-microbial agent. *Indian J Chem.* 2006;45B:526–531.
16. Chitre KP, Jayswal PK, Patel DH. Synthesis, characterization and microbial studies of arylidene aceto hydrazido benzotriazole derivatives. *Asian J Chem.* 2005;17(4):2797–2799.
17. Sukla DK, Srivatsava SD. Synthesis of some new 5-[2-[(1,2,3-benzotriazole)-1-yl-methyl]-1'-(4'-substituted aryl-3'-chloro-2'oxo azetidene)]-amino-1, 3, 4-thiadiazoles: anti-fungal and anti-bacterial agents. *Indian J Chem.* 2008;47B:463–469.
18. Kalesaraj R, Kuru PA. Investigation on the anthelmintic principle of *Butea frondosa* seeds. *Indian J Pharm.* 1962;24:63–65.

19. Sharma BK. Text Book of Spectroscopy. In: . 21st ed. Meerut, India: Goel Publishing House; 2011:283–284.
20. Kemp W. *Organic Spectroscopy*. 3rd ed. New York: Palgrave publishers; 1991:171–176.
21. Vigar Z. *Atlas of Medical Paracitology*. Singapur: P.G. Publishing House; 1984:216–217.
22. Kumar A, Lakshman K, Jayaveera KN, Nandeesh R, Manoj B, Ranganayakulu D. Comparative in vitro anthelmintic activity of three plants from the Amaranthaceae family. *Arch Biol Sci*. 2010;62:185–189.
23. Sucheta GA, Asha KA, Jadhav BG, Deshpande RN, Salvekar PJ. Anthelmintic activity of *Cassia auriculata* L. extracts-In vitro study. *J Nat Prod Plant Resour*. 2011;1(2):62–66.
24. Singh D, Vasudeva P, Dalela D, Sankhwar SN. *Ascaris lumbricoides*: a stranger in the urinary bladder causing urinary retention. *Case Snippet*. 2010;56(3):222–223.
25. Dollery CT. Mebendazole. In: *Therapeutic Drugs*. 2nd ed. Edinburgh: Churchill Livingstone; 1999:M12–M15.
26. EMEA. *European Medicines Evaluation Agency*. Mebendazole Summary Report by CVMP. EMEA/MRL/625/99-Final. London: EMEA; 1999.
27. EMEA. *European Medicines Evaluation Agency*. Mebendazole Summary Report 2 by CVMP. EMEA/MRL/781/01- Final. London: EMEA; 2001.
28. Ji-ichiro S, Rajagopal R, Sunil C, Yoshihito G, Roth AJ, Tapas M. The anthelmintic drug mebendazole induces mitotic arrest and apoptosis by depolymerizing tubulin in non-small cell lung cancer cells. *Mol Cancer Ther*. 2002;1:1201–1209.
29. Pawar SS, Gorde PL, Kakde RB. Synthesis of new N<sup>1</sup>-substituted benzotriazoles as anthelmintic agents. *Arch Appl Sci Res*. 2010;2(1):80–85.
30. Jongsuksuntigul P, Jeradit C, Pornpattanakul S, Charanasri U. A comparative study on the efficacy of albendazole and mebendazole in the treatment of ascariasis hookworm infection and trichuriasis. *Southeast Asian J Trop Med Public Health*. 1993;24(4):724–729.